WO2012131707A3 - Crystalline form of bortezomib, preparation method and pharmaceutical composition there f - Google Patents

Crystalline form of bortezomib, preparation method and pharmaceutical composition there f Download PDF

Info

Publication number
WO2012131707A3
WO2012131707A3 PCT/IN2012/000196 IN2012000196W WO2012131707A3 WO 2012131707 A3 WO2012131707 A3 WO 2012131707A3 IN 2012000196 W IN2012000196 W IN 2012000196W WO 2012131707 A3 WO2012131707 A3 WO 2012131707A3
Authority
WO
WIPO (PCT)
Prior art keywords
bortezomib
crystalline form
preparation
pharmaceutical composition
provides
Prior art date
Application number
PCT/IN2012/000196
Other languages
French (fr)
Other versions
WO2012131707A2 (en
Inventor
Srivardhana Rao JAMJANAM
Venkata Ramakrishna Murthy MOTURU
Venkata Lakshmi Narasimha Rao Dammalapati
Seeta Ramanjaneyulu Gorantla
Original Assignee
Laurus Labs Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Private Limited filed Critical Laurus Labs Private Limited
Publication of WO2012131707A2 publication Critical patent/WO2012131707A2/en
Publication of WO2012131707A3 publication Critical patent/WO2012131707A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

The present invention provides a novel crystalline form AL of bortezomib and a process for its preparation. The present invention also provides a pharmaceutical composition using the novel crystalline form AL of bortezomib.
PCT/IN2012/000196 2011-03-28 2012-03-23 Novel crystalline form of bortezomib, process for the preparation and pharmaceutical composition thereof WO2012131707A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN957CH2011 2011-03-28
IN957/CHE/2011 2011-03-28

Publications (2)

Publication Number Publication Date
WO2012131707A2 WO2012131707A2 (en) 2012-10-04
WO2012131707A3 true WO2012131707A3 (en) 2012-11-29

Family

ID=46932017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000196 WO2012131707A2 (en) 2011-03-28 2012-03-23 Novel crystalline form of bortezomib, process for the preparation and pharmaceutical composition thereof

Country Status (1)

Country Link
WO (1) WO2012131707A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693271A (en) * 2015-02-02 2015-06-10 杭州华东医药集团新药研究院有限公司 Bortezomib crystal form, preparation method, pharmaceutical composition and application thereof
CN106770877A (en) * 2017-03-29 2017-05-31 昆明贵研药业有限公司 A kind of detection method of bortezomib chiral isomer

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630287A (en) 2012-11-16 2016-07-29 Shilpa Medicare Ltd Crystalline bortezomib process
WO2014097306A1 (en) * 2012-12-21 2014-06-26 Natco Pharma Limited Stable and pure polymorphic form of bortezomib
WO2014102755A1 (en) * 2012-12-31 2014-07-03 Shilpa Medicare Limited Bortezomib formulations
KR101763106B1 (en) 2014-02-14 2017-08-01 주식회사 경보제약 Novel Crystalline Form of Bortezomib and Preparation Method Thereof
EP3583110A1 (en) * 2017-02-17 2019-12-25 Fresenius Kabi Oncology Ltd An improved process for the preparation of boronic acid esters
US11964993B2 (en) * 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036281A2 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
CN101899062A (en) * 2009-05-26 2010-12-01 上海威智医药科技有限公司 Synthesis technology of alpha-chiral boric acid and boric acid ester
WO2011099018A1 (en) * 2010-02-15 2011-08-18 Hetero Research Foundation Polymorphs of bortezomib
WO2011107912A1 (en) * 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036281A2 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
CN101899062A (en) * 2009-05-26 2010-12-01 上海威智医药科技有限公司 Synthesis technology of alpha-chiral boric acid and boric acid ester
WO2011099018A1 (en) * 2010-02-15 2011-08-18 Hetero Research Foundation Polymorphs of bortezomib
WO2011107912A1 (en) * 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104693271A (en) * 2015-02-02 2015-06-10 杭州华东医药集团新药研究院有限公司 Bortezomib crystal form, preparation method, pharmaceutical composition and application thereof
CN104693271B (en) * 2015-02-02 2017-08-01 杭州华东医药集团新药研究院有限公司 A kind of Bortezomib crystal form, preparation method and its pharmaceutical composition and purposes
CN106770877A (en) * 2017-03-29 2017-05-31 昆明贵研药业有限公司 A kind of detection method of bortezomib chiral isomer

Also Published As

Publication number Publication date
WO2012131707A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
WO2012156998A3 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
AP2014007774A0 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PL2791093T3 (en) Process for the preparation of 2, 3, 3, 3 tetrafluoropropene
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2014041560A3 (en) Process for the preparation of teneligliptin
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2013068850A3 (en) PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
EP2700322A4 (en) Composition containing scirpusin b, and process for producing composition containing scirpusin b
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.
EP2742946A4 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
WO2013072938A3 (en) Process for the preparation of roflumilast
EP2634183B8 (en) Method for preparing 1,3,5-trioxane
EP2575465A4 (en) Salts of raltegravir
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12765617

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12765617

Country of ref document: EP

Kind code of ref document: A2